
La regulación y financiación de los medicamentos biosimilares en la OCDE

Retorno social de la inversión en salud

Innovación y regulación en biomedicina: obligados a entenderse

The Impact of Severe Obesity on Healthcare Resource Utilisation in Spain

An estimate of the cost of administering intravenous biological agents in Spanish day hospitals

Social economic costs of type 1 diabetes mellitus in pediatric patients in Spain: CHRYSTAL observational study

Women with urinary incontinence in Spain: Health-related quality of life and the use of healthcare resources

Pharmacoeconomic assessment of Pegaspargase versus Asparaginase in acute lymphocytic leukemia

Newsrare 2. Registros de pacientes y medicamentos huérfanos